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Abstract
Introduction Intrathecal baclofen treatment (ITB) is widely
used in children with cerebral palsy. Although this treatment
effectively reduces spasticity, diverse side effects are
reported.
Case report We report about a boy with severe asphyxia-
induced encephalopathy with bilateral cerebral palsy. After
starting the intrathecal baclofen treatment, he episodically
showed symptoms of severe gastroesophageal reflux with pale
skin color, vomiting, massive drooling, acid regurgitation, and
reduced well-being. An open ventral semifundoplication was
done some years ago to treat a gastroesophageal reflux. These
symptomatic episodes occurred strongly dose-dependent and
were not observed during the short test procedure.
Conclusion For the first time, a strong dose-dependent treat-
ment with ITB was documented as a cause for the above
episodes and relapsing re-herniations.
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Introduction
The use of a continuous intrathecal infusion of baclofen by a
pump connected to an intrathecal catheter is widely used in
the treatment of children with bilateral spastic cerebral palsy
(CP) [1]. Parents of children with CP, who have received
this treatment, frequently report an increase in quality of life
and positive effects regarding the spasticity [2]. Besides the
reduction of spasticity, some studies document a weight
gain, a reduction of pain, and an improvement in the ease
of care after admission of intrathecal baclofen in children
with quadriplegia [3, 4]. Even if this therapeutic procedure
requires a high initial financial investment, the cost-
effectiveness of intrathecal baclofen treatment (ITB) is
calculable.
On the other hand, several complications of ITB are
reported in numerous case series as well as in some studies,
in part device-related such as catheter breakage, malfunctions,
or disconnections, and, rarely, pump dysfunctions or compli-
cations associated with the therapy procedure such as infec-
tions, overdoses, severe withdrawal syndrome in case of
malfunction, or hypermobility and hypotonia [5]. In some
studies associated with the therapy-induced reduction of the
tonus, the progression of scoliosis in patients with bilateral
cerebral palsy is discussed [6], although these results are
inconsistent [7].
Neurologically impaired children frequently suffer from a
gastroesophageal reflux. Several causes are discussed to
account for this high incidence of gastroesophageal reflux
in children with cerebral palsy such as prolonged supine
position, increased intra-abdominal pressure associated with
spasticity and/or scoliosis, or hiatus hernia [8].
To our knowledge, and for the first time, we report about
a relapse of a hiatus hernia after semifundoplication as a
complication of an intrathecal baclofen therapy by a pump.
Case report
Caused by a perinatal hypoxic–ischemic encephalopathy, a
14-year-old boy suffers from severe nonambulatory quadri-
plegic cerebral palsy (GMFCS level V) associated with
symptomatic epilepsy, progressive scoliosis, and spastic
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hip luxation, operated 3 years ago. In addition, the boy
suffered from a severe gastroesophageal reflux with regur-
gitation, vomiting, and failure to thrive beginning at the age
of 2. At the age of 6, a hiatus hernia was diagnosed. Despite
conservative therapy, a progression of esophagitis was doc-
umented. Thereafter, at the age of 7, the boy was operatively
treated by an open ventral semifundoplication and percuta-
neous endoscopic gastrostomy (PEG) tube placement. After
this intervention, the gastroesophageal symptoms were sig-
nificantly reduced.
At 14 years of age, in a test of ITB using a continuous
infusion by an external pump, a positive effect on spasticity
was documented. During the ITB test, with a dose of
300 μg/24 h, the spasticity was reduced, as was clinically
the aim. With respect to this experience and result, care-
givers and professionals decided to implant a programmable
SynchroMed II pump (Medtronic Inc.) 6 weeks later.
After implantation, the dose was stepwise increased to
the aim dose, which successfully decreased the spasticity
during the test. Three weeks after reaching the dose of
300 μg/24 h, the boy was acute admitted with pale skin
color, vomiting, massive drooling, acid regurgitation, and
reduced well-being. The clinical examination and the blood
sample, to exclude any metabolic problem or infection, were
normal. No malfunction of the pump or dislocation of the
catheter was found, and the PEG tube position was ade-
quate. After removing the air from the stomach through the
PEG tube and abstinence from food through the tube, the
boy recovered slowly over the course of 3 days.
This situation repeated 2 weeks later. The chest X-ray and a
single-contrast barium swallow study disclosed a relapse from
a large hiatus hernia (Fig. 1). In this situation, the baclofen
dose was stepwise reduced to 220 μg/24 h.With this dose, the
spasticity was insufficiently reduced. Therefore, two further
trials to increase the dose were done, but therapy with an ITB
dose of >240 μg/24 h was repeatedly associated with the
above-described episodes.
In an ethical commission discussion, an operative inter-
vention with re-semifundoplication was excluded. Today,
the boy is being treated with ITB with 220 μg/24 h—no
further clinical episodes of the hiatus hernia, as described
above, have been observed over 2 years, and a partial oral
feeding is possible, although the spasticity is insufficiently
controlled.
Discussion
Even if in an evidence-based review, the data about the
efficacy of ITB were judged as insufficient [9]; this treat-
ment is often used, and a lot of clinical reports and studies
with small sample sizes report about positive effects in the
reduction of spasticity [1]. Consequently, some consensus
working groups define a state-of-the art procedure to elect
patients who could profit from ITB [10].
Although ITB is a procedure which could have a high
grade of multiple benefits for children with CP, there are a
number of potential side effects. In up to 31 % of surgical
procedures, any complication can occur [5]. In most cases, a
device-related complication occurs, rarely with severe con-
sequences. In addition, some nondevice-related adverse ef-
fects are described such as increased drooling or relevant
hypotonia. Hypotonia induced by ITB is one of the possible
causes for the controversially discussed increase of progres-
sion of scoliosis after insertion of an intrathecal baclofen
pump [6, 7].
Increased intra-abdominal pressure as well as hiatus her-
nia are possible causes of increased incidence of gastro-
esophageal reflux in neurologically impaired children. We
report about a boy with asphyxia-induced severe bilateral
cerebral palsy, who suffered from gastroesophageal reflux
disease. After open semifundoplication and PEG tube place-
ment, he showed a stabile course of these gastrointestinal
symptoms. However, after implantation of an intrathecal
baclofen pump and starting ITB treatment, he developed
severe episodes with symptoms of gastroesophageal reflux
associated with reduced well-being and vegetative symp-
toms. A diagnostic work up, including a single-contrast
barium study, disclosed a relapse of the hiatus hernia, which
was strongly and repeatedly associated with the dose of
intrathecal baclofen.
Although recurrent gastroesophageal reflux after
fundoplication is reported in up to 46 % of neurologically
impaired children [11] and hiatus hernia was identified to be
a risk factor for recurrence of gastroesophageal reflux [12], a
mechanical breakdown of the hiatus hernia is reported in
less than 8 % [13]. In our case, we observed a timely close
Fig. 1 Single-contrast barium swallow study demonstrating a large
hiatus hernia
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connection between a higher dose of intrathecal baclofen
and clinical episodes of hiatus herniation. The cause of this
relation is unknown. We hypothesize that an increased hy-
potonia in the trunk causes a sink down of the trunk follow-
ing increased intra-abdominal pressure. Some additional
reports describe that baclofen is effective in treatment of
hiccup [14]. The mechanism is unknown. Besides a reduc-
tion of the frequency of transient lower esophageal sphincter
relaxation, which reduces the frequency of gastrointestinal
refluxes as a potential stimulus for hiccup, a direct relaxa-
tion of the diaphragm could be discussed. Such a diaphragm
relaxation could be a second potential mechanism of the
observed hiatus hernia relapse in our case.
In summary, although the external pump trial prior to
implantation for intrathecal baclofen in children with CP
allows a precise evaluation of effects and safety [15], not
all potential complications could be excluded in this test
phase. For the first time, with our case, we describe a dose-
dependent close connection between ITB and episodes of
hiatus herniation.
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